Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Robert S. Kania"'
Autor:
Rebecca A. Gallego, Louise Bernier, Hui Chen, Sujin Cho-Schultz, Loanne Chung, Michael Collins, Matthew Del Bel, Jeff Elleraas, Cinthia Costa Jones, Ciaran N. Cronin, Martin Edwards, Xu Fang, Timothy Fisher, Mingying He, Jacqui Hoffman, Ruiduan Huo, Mehran Jalaie, Eric Johnson, Ted W. Johnson, Robert S. Kania, Manfred Kraus, Jennifer Lafontaine, Phuong Le, Tongnan Liu, Michael Maestre, Jean Matthews, Michele McTigue, Nichol Miller, Qiming Mu, Xulong Qin, Shijian Ren, Paul Richardson, Allison Rohner, Neal Sach, Li Shao, Graham Smith, Ruirui Su, Bin Sun, Sergei Timofeevski, Phuong Tran, Shuiwang Wang, Wei Wang, Ru Zhou, Jinjiang Zhu, Sajiv K. Nair
Publikováno v:
Journal of Medicinal Chemistry. 66:4888-4909
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d999b959ba4a9c39000e1572f0c999f
https://doi.org/10.1021/acs.jmedchem.2c02038
https://doi.org/10.1021/acs.jmedchem.2c02038
Autor:
Steve L. Bender, David R. Shalinsky, Patrick O'Connor, Robert S. Kania, Brion W. Murray, Michele A. McTigue, Ellen Y. Wu, Shinji Yamazaki, David A. Rewolinski, Jeffrey H. Chen, Karin Amundson, Grant R. Wickman, Max E. Hallin, Maren L. Grazzini, Helen Y. Zou, Dana D. Hu-Lowe
Purpose: Axitinib (AG-013736) is a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases 1 to 3 that is in clinical development for the treatment of solid tumors. We provide a comprehensive description
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6313a887937a89001180d6a921d7302
https://doi.org/10.1158/1078-0432.c.6517239.v1
https://doi.org/10.1158/1078-0432.c.6517239.v1
Autor:
Steve L. Bender, David R. Shalinsky, Patrick O'Connor, Robert S. Kania, Brion W. Murray, Michele A. McTigue, Ellen Y. Wu, Shinji Yamazaki, David A. Rewolinski, Jeffrey H. Chen, Karin Amundson, Grant R. Wickman, Max E. Hallin, Maren L. Grazzini, Helen Y. Zou, Dana D. Hu-Lowe
Supplementary Figures S1-S7 from Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c8872bcbcbeb83ed6a6c64d3ec7b0f8
https://doi.org/10.1158/1078-0432.22439832
https://doi.org/10.1158/1078-0432.22439832
Autor:
Robert L. Hoffman, Robert S. Kania, Mary A. Brothers, Jay F. Davies, Rose A. Ferre, Ketan S. Gajiwala, Mingying He, Robert J. Hogan, Kirk Kozminski, Lilian Y. Li, Jonathan W. Lockner, Jihong Lou, Michelle T. Marra, Lennert J. Mitchell, Brion W. Murray, James A. Nieman, Stephen Noell, Simon P. Planken, Thomas Rowe, Kevin Ryan, George J. Smith, James E. Solowiej, Claire M. Steppan, Barbara Taggart
Publikováno v:
Journal of Medicinal Chemistry
The novel coronavirus disease COVID-19 that emerged in 2019 is caused by the virus SARS CoV-2 and named for its close genetic similarity to SARS CoV-1 that caused severe acute respiratory syndrome (SARS) in 2002. Both SARS coronavirus genomes encode
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c849279282022a7854304d328352c0f1
Autor:
Robert Hoffman, Robert S. Kania, Mary A. Brothers, Jay F. Davies, Rose A. Ferre, Ketan S. Gajiwala, Mingying He, Robert Jeff Hogan, Kirk Kozminski, Lilian Y. Li, Jonathan W. Lockner, Jihong Lou, Michelle T. Marra, Lennert J. Mitchell J. Mitchell Jr, Brion W. Murray, James A. Nieman, Stephen Noell, Simon P. Planken, Thomas Rowe, Kevin Ryan, George J. Smith III, James E. Solowiej, Claire M. Steppan, Barbara Taggart
The novel coronavirus disease COVID-19 that emerged in 2019 is caused by the virus SARS CoV-2 and named for its close genetic similarity to SARS CoV-1 that caused severe acute respiratory syndrome (SARS) in 2002. Both SARS coronavirus genomes encode
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0278c3250d61c1d99cc6c6ca0a5c4ef7
https://doi.org/10.26434/chemrxiv.12631496
https://doi.org/10.26434/chemrxiv.12631496
Autor:
Simon, Planken, Douglas C, Behenna, Sajiv K, Nair, Theodore O, Johnson, Asako, Nagata, Chau, Almaden, Simon, Bailey, T Eric, Ballard, Louise, Bernier, Hengmiao, Cheng, Sujin, Cho-Schultz, Deepak, Dalvie, Judith G, Deal, Dac M, Dinh, Martin P, Edwards, Rose Ann, Ferre, Ketan S, Gajiwala, Michelle, Hemkens, Robert S, Kania, John C, Kath, Jean, Matthews, Brion W, Murray, Sherry, Niessen, Suvi T M, Orr, Mason, Pairish, Neal W, Sach, Hong, Shen, Manli, Shi, James, Solowiej, Khanh, Tran, Elaine, Tseng, Paolo, Vicini, Yuli, Wang, Scott L, Weinrich, Ru, Zhou, Michael, Zientek, Longqing, Liu, Yiqin, Luo, Shuibo, Xin, Chengyi, Zhang, Jennifer, Lafontaine
Publikováno v:
Journal of medicinal chemistry. 60(7)
Mutant epidermal growth factor receptor (EGFR) is a major driver of non-small-cell lung cancer (NSCLC). Marketed first generation inhibitors, such as erlotinib, effect a transient beneficial response in EGFR mutant NSCLC patients before resistance me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::424669cfffca599d5b525ea1e0d9fe2e
https://pubmed.ncbi.nlm.nih.gov/28287730
https://pubmed.ncbi.nlm.nih.gov/28287730
Autor:
Hengmiao, Cheng, Sajiv K, Nair, Brion W, Murray, Chau, Almaden, Simon, Bailey, Sangita, Baxi, Doug, Behenna, Sujin, Cho-Schultz, Deepak, Dalvie, Dac M, Dinh, Martin P, Edwards, Jun Li, Feng, Rose Ann, Ferre, Ketan S, Gajiwala, Michelle D, Hemkens, Amy, Jackson-Fisher, Mehran, Jalaie, Ted O, Johnson, Robert S, Kania, Susan, Kephart, Jennifer, Lafontaine, Beth, Lunney, Kevin K-C, Liu, Zhengyu, Liu, Jean, Matthews, Asako, Nagata, Sherry, Niessen, Martha A, Ornelas, Suvi T M, Orr, Mason, Pairish, Simon, Planken, Shijian, Ren, Daniel, Richter, Kevin, Ryan, Neal, Sach, Hong, Shen, Tod, Smeal, Jim, Solowiej, Scott, Sutton, Khanh, Tran, Elaine, Tseng, William, Vernier, Marlena, Walls, Shuiwang, Wang, Scott L, Weinrich, Shuibo, Xin, Haiwei, Xu, Min-Jean, Yin, Michael, Zientek, Ru, Zhou, John C, Kath
Publikováno v:
Journal of medicinal chemistry. 59(5)
First generation EGFR TKIs (gefitinib, erlotinib) provide significant clinical benefit for NSCLC cancer patients with oncogenic EGFR mutations. Ultimately, these patients' disease progresses, often driven by a second-site mutation in the EGFR kinase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f69cf3e766e492ce164cc24ad82b59de
https://pubmed.ncbi.nlm.nih.gov/26756222
https://pubmed.ncbi.nlm.nih.gov/26756222
Autor:
E. J. Corey, Robert S. Kania
Publikováno v:
Tetrahedron Letters. 39:741-744
A short synthesis of (±)-palominol (1) and (±)-dolabellatrienone (2) starting from farnesol is reported. Noteworthy steps include an intramolecular pinacol coupling to form a 15-membered carbocyclic diol and subsequent dianion-accelerated oxy-Cope
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0ecebef69187b53eb3f8d4f95b9e5b4
https://doi.org/10.1016/s0040-4039(97)10614-1
https://doi.org/10.1016/s0040-4039(97)10614-1
Publikováno v:
Tetrahedron Letters. 34:6977-6980
The recently developed total synthesis of lactacystin (1) has been improved by using the zirconium enolate derived from (R)- or (S)-2-siloxy-1,2,2-triphenylpropionate which lead stereospecifically to either (6S, 7R) or (6R, 7S) lactacystin, respectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::27d3c6bbc755fa44932d121d0630b3ea
https://doi.org/10.1016/s0040-4039(00)61575-7
https://doi.org/10.1016/s0040-4039(00)61575-7